Phase I, Open Label Study of B-Cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients with Relapsed and/or Refractory Multiple Myeloma

Protocol No
NOVARTIS-ADPT07A12101BCMA-CART
Principal Investigator
Mehdi Hamadani
Phase
I
Summary
The purpose of this study is to find out the optimal dose of an engineered B-cell maturation antigen (BCMA) T cell treatment and to determine if this treatment is safe for people with Multiple Myeloma
Description
BCMA Directed CAR-T Cells in Relapsed And Or Refractory Multiple Myeloma
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL